6-cyano-N,N-diethylnicotinamide | 97483-78-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-cyano-N,N-diethylnicotinamide
• 英文别名: 6-Cyano-N,N-diethyl-3-pyridinecarboxamide；6-cyano-N,N-diethylpyridine-3-carboxamide
• CAS: 97483-78-8
• 化学式: C₁₁H₁₃N₃O
• 分子量: 203.244
• InChiKey: JZHCAWSDWIKEMI-UHFFFAOYSA-N

物化性质

• 熔点：
  82-83 °C
• 沸点：
  402.9±30.0 °C(Predicted)
• 密度：
  1.13±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-cyano-N,N-diethylnicotinamide 在 一水合肼 、 亚硝酸异戊酯 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 N,N-diethyl-6-(1,2,4,5-tetrazin-3-yl)nicotinamide
  参考文献：
  名称：

  Synthesis and Evaluation of Nicotinic Acid Derived Tetrazines for Bioorthogonal Labeling

  摘要：

  A set of nicotinic acid derived tetrazines were synthesized and evaluated for activity in inverse-electron-demand Diels-Alder (IEDDA) reactions with various dienophiles. It was found that the performance of these tetrazines is governed by two factors. Theoretical and experimental investigations showed that steric effects may override the energetically predicted order of reactivity. Making a compromise between reactivity and stability, a selected tetrazine was incorporated into a deoxynucleotide to afford a bioorthogonalized building block enabling IEDDA-based tagging schemes of nucleic acids.

  DOI：

  10.1055/s-0034-1380721
• 作为产物：
  描述：

  尼可刹米 在 双氧水 、 三乙胺 作用下， 以 水 、 溶剂黄146 、 乙腈 为溶剂， 反应 7.0h， 生成 6-cyano-N,N-diethylnicotinamide
  参考文献：
  名称：

  Sakamoto, Takao; Kaneda, Soh-ichi; Nishimura, Sumiko, Chemical and pharmaceutical bulletin, 1985, vol. 33, # 2, p. 565 - 571

  摘要：

  DOI：

文献信息

• 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1424336A1

  公开（公告）日：2004-06-02

  This invention provides a compound represented by the formula (I) : wherein R1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I) , which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  这项发明提供了一种由以下式（I）表示的化合物： 其中R1是氢原子、卤素原子、羟基、硝基、可选择具有卤素取代基的烷基、可选择具有取代基的烷氧基、酰基或氨基； R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡啶并嘧啶基、吲哚基、四氢喹啉基或噻唑基，每种基团可能具有取代基； n为1或2；或其盐。该发明提供了一种安全的药物，包括具有优异的凋亡抑制作用和MIF结合作用的式（I）化合物，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤病变、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等。
• A Bifunctional Reagent Designed for the Mild, Nucleophilic Functionalization of Pyridines
  作者：Patrick S. Fier

  DOI：10.1021/jacs.7b05414

  日期：2017.7.19

  the direct functionalization of pyridines. These reactions occur under mild conditions and exhibit broad functional group tolerance, enabling the late-stage functionalization of drug-like molecules. The reagent can be easily prepared on large scale from inexpensive reagents, and reacts in the title reaction with acetonitrile, sodium chloride, and sodium methanesulfonate as the sole byproducts. Although

  本文报道了一种用于吡啶直接官能化的试剂的设计和应用。这些反应发生在温和的条件下，表现出广泛的官能团耐受性，使类药物分子的后期功能化成为可能。该试剂可以很容易地由廉价试剂大规模制备，在标题反应中与乙腈、氯化钠和甲磺酸钠反应，作为唯一的副产物。虽然本通讯主要关注与氰化物作为亲核试剂的反应，但与其他亲核试剂的初步实验预示了这种方法的广泛合成效用。
• 1, 3-benzothiazinone derivatives and use thereof
  申请人：Kajino Masahiro

  公开号：US20050032786A1

  公开（公告）日：2005-02-10

  This invention provides a compound represented by the formula (I): wherein R 1 is a hydrogen atom, a halogen atom, hydroxy, nitro, optionally halogenated alkyl, alkoxy optionally having substituents, acyl or amino optionally having substituents; R 2 is pyridyl, furyl, thienyl, pyrrolyl, quinolyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, tetrahydroquinolyl or thiazolyl, each of which may have substituents; n is 1 or 2; or a salt. And this invention provides a safe pharmaceutical comprising the compound of the formula (I), which has an excellent apoptosis inhibitory effect and MIF binding effect, for preventing and/or treating heart disease, nervous degenerative disease, cerebrovascular disease, central nervous infectious disease, traumatorathy, demyelinating disease, bone and articular disease, kidney disease, liver disease, osteomyelodysplasia, AIDS, cancer, and the like.

  该发明提供了一个由式(I)表示的化合物：其中R1是氢原子、卤素原子、羟基、硝基、可选取代卤代烷基、可选取代基的烷氧基、酰基或氨基；R2是吡啶基、呋喃基、噻吩基、吡咯基、喹啉基、吡嗪基、嘧啶基、吡嗪啉基、吲哚基、四氢喹啉基或噻唑基，每个基团都可以有取代基；n为1或2；或其盐。该发明提供了一种安全的药物，包括式(I)化合物，具有出色的抑制细胞凋亡和结合MIF的效果，用于预防和/或治疗心脏病、神经退行性疾病、脑血管疾病、中枢神经感染性疾病、创伤性疾病、脱髓鞘疾病、骨骼和关节疾病、肾脏疾病、肝脏疾病、骨髓发育不良、艾滋病、癌症等疾病。
• SAKAMOTO, TAKAO;KANEDA, SOH-ICHI;NISHIMURA, SUMIKO;YAMANAKA, HIROSHI, CHEM. AND PHARM. BULL., 1985, 33, N 2, 565-571
  作者：SAKAMOTO, TAKAO、KANEDA, SOH-ICHI、NISHIMURA, SUMIKO、YAMANAKA, HIROSHI

  DOI：——

  日期：——
• US7399759B2
  申请人：——

  公开号：US7399759B2

  公开（公告）日：2008-07-15